Interviews

Robert Rifkin, MD, Discusses Overcoming Lingering Biosimilar Education Gaps

December 5th 2020

Robert Rifkin, MD, FACP, oncologist and hematologist with Rocky Mountain Cancer Centers and medical director of Biosimilars for McKesson, discusses how his practice is working to correct biosimilar education gaps among physicians and the consequences if those gaps are not addressed.

Part 2: Jorge Garcia on Giving Pharmacists Latitude to Switch to Biosimilars

November 25th 2020

Video

Jorge Garcia, PharmD, MS, MHA, MBA, assistant vice president of the System Oncology Pharmacy Service Line at Baptist Health South Florida, discussed how Baptist Health increases biosimilar use and how innovator companies fight to avoid biosimilar competition.

Jorge Garcia Talks About COVID-19’s Effect on Pegfilgrastim Biosimilars

November 18th 2020

Video

Jorge Garcia, MS, assistant vice president of the System Oncology Pharmacy Service Line at Baptist Health South Florida, discussed how the pandemic has interrupted oncology care for patients and affected the utilization of pegfilgrastim biosimilars.

Part 2: Nabeel Khan, MD, Discusses the Significance of a VA Study on Biosimilar Switching

November 7th 2020

Video

Nabeel Khan, MD, an associate professor of clinical medicine with the University of Pennsylvania, explains how a recent infliximab switching study builds support for use of biosimilars and early treatment with these agents.

Part 1: Nabeel Khan, MD, Discusses an Infliximab Double-Switching Study

November 4th 2020

Video

Nabeel Khan, MD, an associate professor of clinical medicine with the University of Pennsylvania, discussed a study in which patients were switched from reference and biosimilar forms of infliximab to another biosimilar infliximab, Renflexis.

Bhuvana Sagar, MD, Discusses Maintaining Cost Efficiency While Using Biosimilars

November 1st 2020

Video

Bhuvana Sagar, MD, the national medical executive at Cigna Health Care, discusses the importance of maintaining cost efficiency when juggling multiple biosimilars for 1 originator in the practice setting.

Part 2: Chad Pettit on “Head-to-Head” Biologics Competition

October 29th 2020

Video

Chad Pettit, executive director of marketing and team leader for global biosimilar launches at Amgen, discusses the potential for a level playing field for biosimilars and reference products.

Part 1: Chad Pettit on Amgen’s Assessment of the US Biosimilar Marketplace

October 27th 2020

Video

Chad Pettit, MBA, executive director of marketing and team leader for global biosimilar launches at Amgen, discussed Amgen’s recent report on the state of the US biosimilars marketplace.

Sandoz’ Edward Li on Using Filgrastim to Ease the Risk of Febrile Neutropenia

October 20th 2020

Video

Edward Li, PharmD, director of Health Economics and Outcomes Research for Sandoz, discussed how biosimilar filgrastim (Zarxio) used as primary prophylaxis saves money and helps reduce the risk of febrile neutropenia in patients with cancer.

Thomas Wakim On Neuclone’s Early Dive Into Developing PD-1 Inhibitor Biosimilars

October 15th 2020

Video

Thomas Wakim, strategic analyst for Neuclone, discussed the company’s decision to break into the world of PD-1 inhibitors, its partnership with the Serum Institute in India, and Neuclone’s biosimilar pipeline.